Home | Newsroom | QIA participates in Series C financing in JenaValve Technology, Inc.

QIA participates in Series C financing in JenaValve Technology, Inc.

8/31/2022


-QIA takes part in $100 million Series C financing 

-JenaValve designs, develops, and commercializes transcatheter heart valve solutions 

-The financing will support the development of an innovative treatment for heart patients 


Irvine, California, 31 August 2022: QIA participated in $100 million Series C financing in JenaValve Technology, Inc. (“JenaValve”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems. 

The financing was led by Bain Capital Life Sciences and included participation from existing investors Andera Partners, Valiance Advisors, Gimv, Cormorant Asset Management, RMM, and Venture Incubator. 

In addition to QIA, other new investors joining the syndicate included Pictet Alternative Advisors SA, Innovatus Capital Partners, and Peijia Medical Limited. 

Proceeds from the financing will enable JenaValve to complete the Company’s investigational device exemption (IDE) pre-market approval (PMA) study to obtain FDA approval for its Trilogy Heart Valve System, a treatment for high surgical risk patients with symptomatic, severe aortic regurgitation (AR). 

In addition, JenaValve will use the proceeds to bolster its real-world data development initiatives in Europe, as well as to expand its worldwide manufacturing capabilities.